Analysis of market concentration ratio of anti-infective drugs in ChinaZHANG Mu-yu, HAN Sheng, GUAN Xiao-dong, YU Xiao-ting, SHI Lu-wen1445-1450
Production efficiency of sub-industries of Chinese pharmaceutical manufacturingWANG Xiu-ming, QIU Jia-xue1451-1455
A few issues in clinical trials of new drugs of traditional Chinese medicine for treating hepatic fibrosisPEI Xiao-jing1460-1461
Application of urinary NAG in renal safety evaluation of TCM in an initial human trial李睿, 唐旭东, 高洪阳, 赵迎盼, 侯金茹, 王淑阁, 赵阳, 高蕊1462-1466
Critical considerations on new drug carcinogenicity evaluationZHANG Jing-xuan, WEI Jin-feng, YE Xiang-feng, XIAO Xi-long, WANG Ai-ping1467-1470
Research progress in the application of mesoporous silica nanoparticles in drug delivery systemsLI Xiao-xi, CHEN Lu, YANG Mei-yan1471-1476
Characterization and selection of recombinant cell line candidates expressing fully-human mAbs against human IgEZHANG Yin-chuan, PAN Yong-bing, LIU Meng-meng, GUI Fang, ZHANG Ya-ting, ZHANG Ai-hua, BI Lan1477-1483
Action mechanisms and application of probiotics in intestinal diseasesZHOU Jie, ZHU Jun-ping, ZHU Xin-ping1484-1487